Vir Biotechnology and Alnylam Pharmaceuticals are going to collaborate on a RNAi therapeutics targeting to SARS-CoV-2 genome. Alnylam screened over 350 small interfering RNAs (siRNAs) to decide on one candidate – VIR-2703 – to progress into pre-clinical development.

The partners are hoping to meet with the FDA to discuss an accelerated path for filing an investigational new drug application at around the end of 2020.

Vir CEO George Scangos said: “Vir is committed to applying industry-leading technologies in our fight against Covid-19.

“Our fruitful and expansive collaboration with Alnylam has rapidly led to identification of a development candidate targeting SARS-CoV-2.

“With this candidate now in hand, we will further accelerate our efforts and plan to begin studies in humans at or around year-end.

“Our ultimate goal would be to provide rapid worldwide access, if approved, to an effective therapeutic to combat Covid-19.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.